Developers claim that a trial vaccine aimed at fighting COVID-19 has prompted an immune response in healthy adults. The vaccine produces antibodies that can neutralize the novel coronavirus. Final testing will take place this fall, and the government hopes to have final trial results by the end of the year 2020. This would be a “record-setting speed for developing a vaccine.”
While many patients incurred “minor” side effects, the drug was found to be well-tolerated and safe overall. Anthony S. Fauci, M.D., who is Director of the National Institute of Allergy and Infectious Disease (NIAID), has hailed the early-stage results as a win.
The vaccine is also known as mRNA-1273 and is being co-developed by the NIAID and Moderna, Inc. If successful, it will require two doses separated by a month.

By: Samuel Won, PharmD Candidate 2021
For the full article, please visit:

Moderna’s COVID-19 vaccine spurs immune response in trial

Leave a comment

Your email address will not be published. Required fields are marked *

Web Design by Venbit
Privacy Policy